Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)

We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant‐ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six‐week cycle followed by eight fiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Dai, Iida, Shinsuke, Ogawa, Gakuto, Fukuhara, Noriko, Seo, Sachiko, Miyazaki, Kana, Yoshimitsu, Makoto, Kuroda, Junya, Tsukamoto, Norifumi, Tsujimura, Hideki, Hangaishi, Akira, Yamauchi, Takahiro, Utsumi, Takahiko, Mizuno, Ishikazu, Takamatsu, Yasushi, Nagata, Yasuyuki, Minauchi, Koichiro, Ohtsuka, Eiichi, Hanamura, Ichiro, Yoshida, Shinichiro, Yamasaki, Satoshi, Suehiro, Youko, Kamiyama, Yutaro, Tsukasaki, Kunihiro, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891591/
https://www.ncbi.nlm.nih.gov/pubmed/32583431
http://dx.doi.org/10.1111/bjh.16878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891591/
https://www.ncbi.nlm.nih.gov/pubmed/32583431
http://dx.doi.org/10.1111/bjh.16878

Ejemplares similares